JP2022191210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022191210A5 JP2022191210A5 JP2022128871A JP2022128871A JP2022191210A5 JP 2022191210 A5 JP2022191210 A5 JP 2022191210A5 JP 2022128871 A JP2022128871 A JP 2022128871A JP 2022128871 A JP2022128871 A JP 2022128871A JP 2022191210 A5 JP2022191210 A5 JP 2022191210A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- conjugate
- vedotin
- antigen
- targeting molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 229960000575 trastuzumab Drugs 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 6
- 239000001007 phthalocyanine dye Substances 0.000 claims 6
- 125000004474 heteroalkylene group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229940049679 trastuzumab deruxtecan Drugs 0.000 claims 5
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 claims 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 229950009791 durvalumab Drugs 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 229910052710 silicon Inorganic materials 0.000 claims 4
- 229940121497 sintilimab Drugs 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229960003989 tocilizumab Drugs 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 229950002916 avelumab Drugs 0.000 claims 3
- 229960004669 basiliximab Drugs 0.000 claims 3
- 229940121420 cemiplimab Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- -1 heteroalkenylene Chemical group 0.000 claims 3
- 229950005674 modotuximab Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 239000010703 silicon Substances 0.000 claims 3
- JACPFCQFVIAGDN-UHFFFAOYSA-M sipc iv Chemical compound [OH-].[Si+4].CN(C)CCC[Si](C)(C)[O-].C=1C=CC=C(C(N=C2[N-]C(C3=CC=CC=C32)=N2)=N3)C=1C3=CC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 JACPFCQFVIAGDN-UHFFFAOYSA-M 0.000 claims 3
- 229950007213 spartalizumab Drugs 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229940125568 MGD013 Drugs 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 229950008459 alacizumab pegol Drugs 0.000 claims 2
- 229950005725 arcitumomab Drugs 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229950009653 camidanlumab Drugs 0.000 claims 2
- 229950007712 camrelizumab Drugs 0.000 claims 2
- 229940067219 cetrelimab Drugs 0.000 claims 2
- 229940011248 cosibelimab Drugs 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- 229950008925 depatuxizumab mafodotin Drugs 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 229950002140 futuximab Drugs 0.000 claims 2
- 229940121448 gancotamab Drugs 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229950006359 icrucumab Drugs 0.000 claims 2
- 229950005646 imgatuzumab Drugs 0.000 claims 2
- 229950007937 inolimomab Drugs 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229950010860 laprituximab emtansine Drugs 0.000 claims 2
- 229940121292 leronlimab Drugs 0.000 claims 2
- 229950003135 margetuximab Drugs 0.000 claims 2
- 229950008001 matuzumab Drugs 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229960000513 necitumumab Drugs 0.000 claims 2
- 229950010203 nimotuzumab Drugs 0.000 claims 2
- 229960003347 obinutuzumab Drugs 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 229950010773 pidilizumab Drugs 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229960002633 ramucirumab Drugs 0.000 claims 2
- 229940060041 satralizumab Drugs 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims 2
- 229950007123 tislelizumab Drugs 0.000 claims 2
- 229940121514 toripalimab Drugs 0.000 claims 2
- 229960005267 tositumomab Drugs 0.000 claims 2
- 229950007217 tremelimumab Drugs 0.000 claims 2
- 229950008250 zalutumumab Drugs 0.000 claims 2
- 229950007157 zolbetuximab Drugs 0.000 claims 2
- MFZSNESUTRVBQX-XEURHVNRSA-N (2S)-2-amino-6-[4-[[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]disulfanyl]pentanoylamino]hexanoic acid Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSSC(C)CCC(=O)NCCCC[C@H](N)C(O)=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 MFZSNESUTRVBQX-XEURHVNRSA-N 0.000 claims 1
- RCSZIBSPHRZNRQ-BTZXMIIFSA-N (2S)-2-amino-6-[6-[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(2S)-3-(1H-indol-3-yl)-1-(oxazinan-2-yl)-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylamino]hexanoylamino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCNC(=O)CCCCCN(C)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(=O)N1OCCCC1)CC1=CNC2=CC=CC=C12 RCSZIBSPHRZNRQ-BTZXMIIFSA-N 0.000 claims 1
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 229940126609 CR6261 Drugs 0.000 claims 1
- 229940126626 Ektomab Drugs 0.000 claims 1
- 229940126611 FBTA05 Drugs 0.000 claims 1
- BRDWIEOJOWJCLU-LTGWCKQJSA-N GS-441524 Chemical compound C=1C=C2C(N)=NC=NN2C=1[C@]1(C#N)O[C@H](CO)[C@@H](O)[C@H]1O BRDWIEOJOWJCLU-LTGWCKQJSA-N 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 229940126614 Iomab-B Drugs 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 claims 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 claims 1
- 229950005186 abagovomab Drugs 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 229940005624 abrezekimab Drugs 0.000 claims 1
- 229950008347 abrilumab Drugs 0.000 claims 1
- 229950004283 actoxumab Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229950009084 adecatumumab Drugs 0.000 claims 1
- 229950008995 aducanumab Drugs 0.000 claims 1
- 229960003227 afelimomab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960004539 alirocumab Drugs 0.000 claims 1
- 229950009106 altumomab Drugs 0.000 claims 1
- 229950001537 amatuximab Drugs 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229950006061 anatumomab mafenatox Drugs 0.000 claims 1
- 229950004189 andecaliximab Drugs 0.000 claims 1
- 229950006588 anetumab ravtansine Drugs 0.000 claims 1
- 229950010117 anifrolumab Drugs 0.000 claims 1
- 229950005794 anrukinzumab Drugs 0.000 claims 1
- 229950003145 apolizumab Drugs 0.000 claims 1
- 229950009583 atidortoxumab Drugs 0.000 claims 1
- 229950005122 atinumab Drugs 0.000 claims 1
- 229940052375 azintuxizumab vedotin Drugs 0.000 claims 1
- 229950001863 bapineuzumab Drugs 0.000 claims 1
- 229950007843 bavituximab Drugs 0.000 claims 1
- 229950003269 bectumomab Drugs 0.000 claims 1
- 229960004965 begelomab Drugs 0.000 claims 1
- 229940018964 belantamab mafodotin Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229950009566 bemarituzumab Drugs 0.000 claims 1
- 229950000321 benralizumab Drugs 0.000 claims 1
- 229950009572 berlimatoxumab Drugs 0.000 claims 1
- 229940121532 bermekimab Drugs 0.000 claims 1
- 229940038699 bersanlimab Drugs 0.000 claims 1
- 229950010015 bertilimumab Drugs 0.000 claims 1
- 229950010559 besilesomab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229950008086 bezlotoxumab Drugs 0.000 claims 1
- 229950001303 biciromab Drugs 0.000 claims 1
- 229950006326 bimagrumab Drugs 0.000 claims 1
- 229950002853 bimekizumab Drugs 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 229950002903 bivatuzumab Drugs 0.000 claims 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 claims 1
- 229950000009 bleselumab Drugs 0.000 claims 1
- 229960003008 blinatumomab Drugs 0.000 claims 1
- 229950011350 bococizumab Drugs 0.000 claims 1
- 229950009342 brazikumab Drugs 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229960002874 briakinumab Drugs 0.000 claims 1
- 229960003735 brodalumab Drugs 0.000 claims 1
- 229950000025 brolucizumab Drugs 0.000 claims 1
- 229950002817 burosumab Drugs 0.000 claims 1
- 229940126608 cBR96-doxorubicin immunoconjugate Drugs 0.000 claims 1
- 229960001838 canakinumab Drugs 0.000 claims 1
- 229950007296 cantuzumab mertansine Drugs 0.000 claims 1
- 229950002176 caplacizumab Drugs 0.000 claims 1
- 108010023376 caplacizumab Proteins 0.000 claims 1
- 229950001178 capromab Drugs 0.000 claims 1
- 229940034605 capromab pendetide Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229950000771 carlumab Drugs 0.000 claims 1
- 229950005629 carotuximab Drugs 0.000 claims 1
- 229960000419 catumaxomab Drugs 0.000 claims 1
- 229950006754 cedelizumab Drugs 0.000 claims 1
- 229950001357 celmoleukin Drugs 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229950001565 clazakizumab Drugs 0.000 claims 1
- 229950002334 clenoliximab Drugs 0.000 claims 1
- 229950002595 clivatuzumab tetraxetan Drugs 0.000 claims 1
- 229950007906 codrituzumab Drugs 0.000 claims 1
- 229950009658 cofetuzumab Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229950007276 conatumumab Drugs 0.000 claims 1
- 229950009735 concizumab Drugs 0.000 claims 1
- 229950001954 crenezumab Drugs 0.000 claims 1
- 229950004730 crizanlizumab Drugs 0.000 claims 1
- 229940085936 cusatuzumab Drugs 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 229950007409 dacetuzumab Drugs 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 229950008135 dectrekumab Drugs 0.000 claims 1
- 229950004079 denintuzumab mafodotin Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229950008962 detumomab Drugs 0.000 claims 1
- 229960004497 dinutuximab Drugs 0.000 claims 1
- 229940121432 dostarlimab Drugs 0.000 claims 1
- 229950009964 drozitumab Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 229940057045 duvortuxizumab Drugs 0.000 claims 1
- 229950000006 ecromeximab Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960001776 edrecolomab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229950002209 efungumab Drugs 0.000 claims 1
- 229950010217 eldelumab Drugs 0.000 claims 1
- 229950005753 elezanumab Drugs 0.000 claims 1
- 229950002519 elgemtumab Drugs 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- 229950004647 emactuzumab Drugs 0.000 claims 1
- 229950004645 emapalumab Drugs 0.000 claims 1
- 229950004255 emibetuzumab Drugs 0.000 claims 1
- 229950006925 emicizumab Drugs 0.000 claims 1
- 229940115415 enapotamab vedotin Drugs 0.000 claims 1
- 229950003048 enavatuzumab Drugs 0.000 claims 1
- 229950004930 enfortumab vedotin Drugs 0.000 claims 1
- 229950000565 enlimomab pegol Drugs 0.000 claims 1
- 229950007313 enokizumab Drugs 0.000 claims 1
- 229950001752 enoticumab Drugs 0.000 claims 1
- 229950009760 epratuzumab Drugs 0.000 claims 1
- 229950006063 eptinezumab Drugs 0.000 claims 1
- 229950001616 erenumab Drugs 0.000 claims 1
- 229950004292 erlizumab Drugs 0.000 claims 1
- 229950008579 ertumaxomab Drugs 0.000 claims 1
- 229950009569 etaracizumab Drugs 0.000 claims 1
- 229940115924 etigilimab Drugs 0.000 claims 1
- 229950004912 etrolizumab Drugs 0.000 claims 1
- 229950004341 evinacumab Drugs 0.000 claims 1
- 229960002027 evolocumab Drugs 0.000 claims 1
- 229940093443 fanolesomab Drugs 0.000 claims 1
- 229950001488 faralimomab Drugs 0.000 claims 1
- 229940116862 faricimab Drugs 0.000 claims 1
- 229950009929 farletuzumab Drugs 0.000 claims 1
- 229950000335 fasinumab Drugs 0.000 claims 1
- 229950010512 fezakinumab Drugs 0.000 claims 1
- 229940126612 fibatuzumab Drugs 0.000 claims 1
- 229950002846 ficlatuzumab Drugs 0.000 claims 1
- 229950008085 figitumumab Drugs 0.000 claims 1
- 229940121282 flotetuzumab Drugs 0.000 claims 1
- 229950004923 fontolizumab Drugs 0.000 claims 1
- 229950004356 foralumab Drugs 0.000 claims 1
- 229950011078 foravirumab Drugs 0.000 claims 1
- 229950011509 fremanezumab Drugs 0.000 claims 1
- 229950004003 fresolimumab Drugs 0.000 claims 1
- 229950009370 fulranumab Drugs 0.000 claims 1
- 229950000118 galcanezumab Drugs 0.000 claims 1
- 229950001109 galiximab Drugs 0.000 claims 1
- 229950004896 ganitumab Drugs 0.000 claims 1
- 229950002508 gantenerumab Drugs 0.000 claims 1
- 229940057296 gatipotuzumab Drugs 0.000 claims 1
- 229950004792 gavilimomab Drugs 0.000 claims 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 1
- 229950003717 gevokizumab Drugs 0.000 claims 1
- 229950009614 gimsilumab Drugs 0.000 claims 1
- 229950002026 girentuximab Drugs 0.000 claims 1
- 229950009672 glembatumumab vedotin Drugs 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 229940126613 gomiliximab Drugs 0.000 claims 1
- 229950010864 guselkumab Drugs 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229950009637 ianalumab Drugs 0.000 claims 1
- 229950010245 ibalizumab Drugs 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 229960002308 idarucizumab Drugs 0.000 claims 1
- 229950002200 igovomab Drugs 0.000 claims 1
- 229950003680 imalumab Drugs 0.000 claims 1
- 229940121287 imaprelimab Drugs 0.000 claims 1
- 229950007354 imciromab Drugs 0.000 claims 1
- 229950005015 inebilizumab Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 claims 1
- 229950001014 intetumumab Drugs 0.000 claims 1
- 229950010939 iratumumab Drugs 0.000 claims 1
- 229940121288 iscalimab Drugs 0.000 claims 1
- 229950009645 istiratumab Drugs 0.000 claims 1
- 229950003818 itolizumab Drugs 0.000 claims 1
- 229960005435 ixekizumab Drugs 0.000 claims 1
- 229950010828 keliximab Drugs 0.000 claims 1
- 229950000518 labetuzumab Drugs 0.000 claims 1
- 229940057958 lacnotuzumab Drugs 0.000 claims 1
- 229950000482 lampalizumab Drugs 0.000 claims 1
- 108010032674 lampalizumab Proteins 0.000 claims 1
- 229950005287 lanadelumab Drugs 0.000 claims 1
- 229950002183 lebrikizumab Drugs 0.000 claims 1
- 229940126615 lendalizumab Drugs 0.000 claims 1
- 229950010470 lerdelimumab Drugs 0.000 claims 1
- 229940058170 letolizumab Drugs 0.000 claims 1
- 229950002884 lexatumumab Drugs 0.000 claims 1
- 229950009923 ligelizumab Drugs 0.000 claims 1
- 229950001237 lilotomab Drugs 0.000 claims 1
- 229950002950 lintuzumab Drugs 0.000 claims 1
- 229950009756 loncastuximab Drugs 0.000 claims 1
- 229950003526 lorvotuzumab mertansine Drugs 0.000 claims 1
- 229950004563 lucatumumab Drugs 0.000 claims 1
- 229950001869 mapatumumab Drugs 0.000 claims 1
- 229940121460 marstacimab Drugs 0.000 claims 1
- 229950008083 maslimomab Drugs 0.000 claims 1
- 229950007254 mavrilimumab Drugs 0.000 claims 1
- 229960005108 mepolizumab Drugs 0.000 claims 1
- 229950005555 metelimumab Drugs 0.000 claims 1
- 229950003734 milatuzumab Drugs 0.000 claims 1
- 229950002142 minretumomab Drugs 0.000 claims 1
- 229950009792 mirikizumab Drugs 0.000 claims 1
- 229950007243 mirvetuximab Drugs 0.000 claims 1
- 229950007699 mogamulizumab Drugs 0.000 claims 1
- 229950001907 monalizumab Drugs 0.000 claims 1
- 229950008897 morolimumab Drugs 0.000 claims 1
- 229950009794 mosunetuzumab Drugs 0.000 claims 1
- 229960001521 motavizumab Drugs 0.000 claims 1
- 229960003816 muromonab-cd3 Drugs 0.000 claims 1
- 229950007708 namilumab Drugs 0.000 claims 1
- 229950009793 naptumomab estafenatox Drugs 0.000 claims 1
- 229950001422 naratuximab emtansine Drugs 0.000 claims 1
- 229940015638 narsoplimab Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229940121585 naxitamab Drugs 0.000 claims 1
- 229960002915 nebacumab Drugs 0.000 claims 1
- 229950010012 nemolizumab Drugs 0.000 claims 1
- 229950009675 nerelimomab Drugs 0.000 claims 1
- 229940121307 netakimab Drugs 0.000 claims 1
- 229940121468 nirsevimab Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229960003419 obiltoxaximab Drugs 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 229950010465 odulimomab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229950008516 olaratumab Drugs 0.000 claims 1
- 229950010006 olokizumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229950000846 onartuzumab Drugs 0.000 claims 1
- 229950002104 ontuxizumab Drugs 0.000 claims 1
- 229940121310 onvatilimab Drugs 0.000 claims 1
- 229950010704 opicinumab Drugs 0.000 claims 1
- 229950009057 oportuzumab monatox Drugs 0.000 claims 1
- 229950007283 oregovomab Drugs 0.000 claims 1
- 229950002610 otelixizumab Drugs 0.000 claims 1
- 229940121480 otilimab Drugs 0.000 claims 1
- 229950000121 otlertuzumab Drugs 0.000 claims 1
- 229950003709 oxelumab Drugs 0.000 claims 1
- 229950009723 ozanezumab Drugs 0.000 claims 1
- 229950004327 ozoralizumab Drugs 0.000 claims 1
- 229950010626 pagibaximab Drugs 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 229950003481 pamrevlumab Drugs 0.000 claims 1
- 229950011485 pascolizumab Drugs 0.000 claims 1
- 229950000037 pasotuxizumab Drugs 0.000 claims 1
- 229950003522 pateclizumab Drugs 0.000 claims 1
- 229960005570 pemtumomab Drugs 0.000 claims 1
- 229940067082 pentetate Drugs 0.000 claims 1
- 229950005079 perakizumab Drugs 0.000 claims 1
- 229950003203 pexelizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims 1
- 229950010074 pinatuzumab vedotin Drugs 0.000 claims 1
- 229940126620 pintumomab Drugs 0.000 claims 1
- 229940126621 pogalizumab Drugs 0.000 claims 1
- 229950009416 polatuzumab vedotin Drugs 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229950003486 ponezumab Drugs 0.000 claims 1
- 229950007082 prasinezumab Drugs 0.000 claims 1
- 229950002228 prezalumab Drugs 0.000 claims 1
- 229950003700 priliximab Drugs 0.000 claims 1
- 229950011407 pritoxaximab Drugs 0.000 claims 1
- 229950009904 pritumumab Drugs 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229950011613 racotumomab Drugs 0.000 claims 1
- 229950002786 rafivirumab Drugs 0.000 claims 1
- 229950009885 ralpancizumab Drugs 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 229940121319 ravagalimab Drugs 0.000 claims 1
- 229960004910 raxibacumab Drugs 0.000 claims 1
- 229950000987 refanezumab Drugs 0.000 claims 1
- 229950005854 regavirumab Drugs 0.000 claims 1
- 229940121484 relatlimab Drugs 0.000 claims 1
- 229960003254 reslizumab Drugs 0.000 claims 1
- 229950003238 rilotumumab Drugs 0.000 claims 1
- 229950007943 risankizumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229940121324 romilkimab Drugs 0.000 claims 1
- 229950010968 romosozumab Drugs 0.000 claims 1
- 229950010316 rontalizumab Drugs 0.000 claims 1
- 229950005380 rosmantuzumab Drugs 0.000 claims 1
- 229950005039 rozanolixizumab Drugs 0.000 claims 1
- 229950005374 ruplizumab Drugs 0.000 claims 1
- 229950001460 sacituzumab Drugs 0.000 claims 1
- 229950000143 sacituzumab govitecan Drugs 0.000 claims 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950000106 samalizumab Drugs 0.000 claims 1
- 229940121326 samrotamab vedotin Drugs 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 229950007308 satumomab Drugs 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- 229950008834 seribantumab Drugs 0.000 claims 1
- 229950003850 setoxaximab Drugs 0.000 claims 1
- 229950004951 sevirumab Drugs 0.000 claims 1
- 229950008684 sibrotuzumab Drugs 0.000 claims 1
- 229950010077 sifalimumab Drugs 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960003323 siltuximab Drugs 0.000 claims 1
- 229950009513 simtuzumab Drugs 0.000 claims 1
- 229940115586 simulect Drugs 0.000 claims 1
- 229950003804 siplizumab Drugs 0.000 claims 1
- 229950006094 sirukumab Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229950003763 sofituzumab vedotin Drugs 0.000 claims 1
- 229950011267 solitomab Drugs 0.000 claims 1
- 229950006551 sontuzumab Drugs 0.000 claims 1
- XNZLMZRIGGHITK-VKXBZTRUSA-N soravtansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCC[C@@H](C(O)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2.CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCC[C@H](C(O)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 XNZLMZRIGGHITK-VKXBZTRUSA-N 0.000 claims 1
- 229950002549 stamulumab Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229950010708 sulesomab Drugs 0.000 claims 1
- 229950001915 suvizumab Drugs 0.000 claims 1
- 229950010265 tabalumab Drugs 0.000 claims 1
- 229950001072 tadocizumab Drugs 0.000 claims 1
- 229940121503 tafasitamab Drugs 0.000 claims 1
- 229950004218 talizumab Drugs 0.000 claims 1
- 229950008160 tanezumab Drugs 0.000 claims 1
- 229950001603 taplitumomab paptox Drugs 0.000 claims 1
- 229940066453 tecentriq Drugs 0.000 claims 1
- 229950001788 tefibazumab Drugs 0.000 claims 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 claims 1
- 229950001289 tenatumomab Drugs 0.000 claims 1
- 229950000301 teneliximab Drugs 0.000 claims 1
- 229950010127 teplizumab Drugs 0.000 claims 1
- 229950010259 teprotumumab Drugs 0.000 claims 1
- 229950009054 tesidolumab Drugs 0.000 claims 1
- 229950008998 tezepelumab Drugs 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 229950004742 tigatuzumab Drugs 0.000 claims 1
- 229950005515 tildrakizumab Drugs 0.000 claims 1
- 229950006757 timolumab Drugs 0.000 claims 1
- 229950007133 tiragolumab Drugs 0.000 claims 1
- 229950001802 toralizumab Drugs 0.000 claims 1
- 229950008836 tosatoxumab Drugs 0.000 claims 1
- 229950000835 tralokinumab Drugs 0.000 claims 1
- 229950010086 tregalizumab Drugs 0.000 claims 1
- 229950004593 ublituximab Drugs 0.000 claims 1
- 229950005972 urelumab Drugs 0.000 claims 1
- 229950004362 urtoxazumab Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 229950003520 utomilumab Drugs 0.000 claims 1
- 229950000302 vadastuximab Drugs 0.000 claims 1
- 229950000449 vanucizumab Drugs 0.000 claims 1
- 229950001067 varlilumab Drugs 0.000 claims 1
- 229960004914 vedolizumab Drugs 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
- 229950004393 visilizumab Drugs 0.000 claims 1
- 229950001212 volociximab Drugs 0.000 claims 1
- 229950003511 votumumab Drugs 0.000 claims 1
- 229950008915 xentuzumab Drugs 0.000 claims 1
- 229940055760 yervoy Drugs 0.000 claims 1
- 229950009002 zanolimumab Drugs 0.000 claims 1
- 229940106067 zinbryta Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008476P | 2020-04-10 | 2020-04-10 | |
| US202063008502P | 2020-04-10 | 2020-04-10 | |
| US63/008,476 | 2020-04-10 | ||
| US63/008,502 | 2020-04-10 | ||
| PCT/US2021/026705 WO2021207691A1 (en) | 2020-04-10 | 2021-04-09 | Phthalocyanine dye compounds, conjugates and methods of use thereof |
| JP2021571480A JP7125828B2 (ja) | 2020-04-10 | 2021-04-09 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571480A Division JP7125828B2 (ja) | 2020-04-10 | 2021-04-09 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022191210A JP2022191210A (ja) | 2022-12-27 |
| JP2022191210A5 true JP2022191210A5 (https=) | 2024-04-19 |
Family
ID=78022788
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571480A Active JP7125828B2 (ja) | 2020-04-10 | 2021-04-09 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
| JP2022126602A Pending JP2022191209A (ja) | 2020-04-10 | 2022-08-08 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
| JP2022128871A Pending JP2022191210A (ja) | 2020-04-10 | 2022-08-12 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571480A Active JP7125828B2 (ja) | 2020-04-10 | 2021-04-09 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
| JP2022126602A Pending JP2022191209A (ja) | 2020-04-10 | 2022-08-08 | フタロシアニン色素化合物、コンジュゲート及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11466158B2 (https=) |
| EP (1) | EP4132583A4 (https=) |
| JP (3) | JP7125828B2 (https=) |
| KR (1) | KR20230009890A (https=) |
| CN (1) | CN115942958A (https=) |
| AU (1) | AU2021251873A1 (https=) |
| BR (1) | BR112022020521A2 (https=) |
| CA (1) | CA3179937A1 (https=) |
| MX (1) | MX2022012721A (https=) |
| WO (1) | WO2021207691A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7760124B2 (ja) * | 2020-02-05 | 2025-10-27 | 国立大学法人 東京大学 | フタロシアニン染料と抗体又はペプチドとのコンジュゲート |
| WO2021207691A1 (en) | 2020-04-10 | 2021-10-14 | Rakuten Medical, Inc. | Phthalocyanine dye compounds, conjugates and methods of use thereof |
| JP2024505556A (ja) | 2021-02-02 | 2024-02-06 | ラクテン・メディカル，インコーポレイテッド | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 |
| US12115223B2 (en) | 2021-04-22 | 2024-10-15 | The University Of Tokyo | Conjugate of biotin-modified dimer and phthalocyanine dye |
| CN113943305B (zh) * | 2021-11-15 | 2022-12-30 | 中国科学技术大学 | 酞菁荧光分子化合物、制备方法、酞菁荧光纳米材料 |
| AU2023221861A1 (en) | 2022-02-18 | 2024-09-05 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
| EP4615863A1 (en) | 2022-11-11 | 2025-09-17 | Rakuten Medical, Inc. | Engineered interleukin-15 polypeptides, complexes and uses thereof |
| EP4435060A1 (en) | 2023-03-23 | 2024-09-25 | Albert-Ludwigs-Universität Freiburg | Silicon phthalocyanine and tribenzophthalocyanine dyes and their use in diagnosis and therapy |
| WO2025035196A1 (pt) * | 2023-08-11 | 2025-02-20 | Use Phitta Cream Ltda - Epp | Creme hidratante com proteção antisséptica de ação prolongada para as mãos |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2082934C (en) * | 1990-05-15 | 2003-08-05 | Walter B. Dandliker | Phthalocyanatopolyethylene glycol, and phthalocyanato saccharides as fluorescent digoxin reagents |
| US6060598A (en) * | 1990-05-15 | 2000-05-09 | Hyperion, Inc. | Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding |
| ES2163393T3 (es) | 1990-05-15 | 2002-02-01 | Hyperion Inc | Porfirina fluorescente y ftalocianina fluorescente - derivados de polietilenglicol, poliol y sacaridos como sondas fluorescentes. |
| US5484778C1 (en) * | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
| US5763602A (en) * | 1996-10-01 | 1998-06-09 | Li; Ying-Syi | Methods of syntheses of phthalocyanine compounds |
| US7005518B2 (en) * | 2002-10-25 | 2006-02-28 | Li-Cor, Inc. | Phthalocyanine dyes |
| CN1315850C (zh) | 2004-06-11 | 2007-05-16 | 福州大学 | 轴向取代酞菁配合物、它的制备及其在光动力治疗中的应用 |
| CN103539799B (zh) | 2013-08-29 | 2016-01-06 | 中国医学科学院生物医学工程研究所 | 一种水溶性氨基多羧酸修饰酞菁化合物的制备方法和用途 |
| EP3046583B1 (en) | 2013-09-18 | 2019-02-13 | Aura Biosciences, Inc. | Virus-like particle conjugates for treatment of tumors |
| ES2889904T3 (es) | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| CA3070469C (en) | 2016-10-25 | 2022-06-21 | Rakuten Medical, Inc. | Light diffusing devices for use in photoimmunotherapy |
| US10416366B2 (en) | 2016-10-25 | 2019-09-17 | Rakuten Medical, Inc. | Light diffusing devices for use in photoimmunotherapy |
| JP2020508323A (ja) * | 2017-02-23 | 2020-03-19 | ラクテン メディカル インコーポレイテッド | 光免疫療法のための治療用組成物および関連する方法 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| EP3649153B8 (en) | 2017-07-06 | 2025-07-16 | Tusk Therapeutics Ltd | Fc optimised anti-cd25 antibodies for tumor specific cell depletion |
| JP2020017910A (ja) | 2018-07-27 | 2020-01-30 | ソニーセミコンダクタソリューションズ株式会社 | ストリーキング補正回路、撮像装置、及び、電子機器 |
| JP7625188B2 (ja) * | 2019-09-30 | 2025-02-03 | 国立大学法人 東京大学 | ビオチン改変二量体とフタロシアニン染料とのコンジュゲート |
| JP7760124B2 (ja) | 2020-02-05 | 2025-10-27 | 国立大学法人 東京大学 | フタロシアニン染料と抗体又はペプチドとのコンジュゲート |
| WO2021207691A1 (en) * | 2020-04-10 | 2021-10-14 | Rakuten Medical, Inc. | Phthalocyanine dye compounds, conjugates and methods of use thereof |
| WO2022216978A1 (en) | 2021-04-09 | 2022-10-13 | Rakuten Medical, Inc. | Phthalocyanine dye compounds, conjugates and methods of use thereof |
-
2021
- 2021-04-09 WO PCT/US2021/026705 patent/WO2021207691A1/en not_active Ceased
- 2021-04-09 CA CA3179937A patent/CA3179937A1/en active Pending
- 2021-04-09 AU AU2021251873A patent/AU2021251873A1/en active Pending
- 2021-04-09 JP JP2021571480A patent/JP7125828B2/ja active Active
- 2021-04-09 KR KR1020227039145A patent/KR20230009890A/ko not_active Withdrawn
- 2021-04-09 BR BR112022020521A patent/BR112022020521A2/pt not_active Application Discontinuation
- 2021-04-09 MX MX2022012721A patent/MX2022012721A/es unknown
- 2021-04-09 CN CN202180042331.XA patent/CN115942958A/zh active Pending
- 2021-04-09 EP EP21783992.7A patent/EP4132583A4/en active Pending
- 2021-09-22 US US17/482,239 patent/US11466158B2/en active Active
-
2022
- 2022-08-08 JP JP2022126602A patent/JP2022191209A/ja active Pending
- 2022-08-12 JP JP2022128871A patent/JP2022191210A/ja active Pending
- 2022-09-23 US US17/934,705 patent/US12448518B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191210A5 (https=) | ||
| JP2017522384A5 (https=) | ||
| US20230391820A1 (en) | Hydrophobic interaction protein chromatography under no-salt conditions | |
| CN109791142B (zh) | 用于确定样品中治疗性单克隆抗体及其相应抗药物抗体的量的通用测定 | |
| US20250230186A1 (en) | Stabilised Protein Solutions | |
| JP2024532726A5 (https=) | ||
| JP2024508886A5 (https=) | ||
| JP2023535842A5 (https=) | ||
| US20180194859A1 (en) | Linked Dual Antibodies Conjugated at a Hinge Region | |
| US12577275B2 (en) | Hydrophobic interaction chromatography carrier and protein purification method | |
| US20250136667A1 (en) | Isolation of therapeutic protein | |
| CA3175685A1 (en) | Auto-injector assembly | |
| EP4659022A1 (en) | System and method for analyzing antibody co-formulations | |
| NZ743923B2 (en) | Chimeric proteins and methods of immunotherapy | |
| NZ743923A (en) | Chimeric proteins and methods of immunotherapy | |
| HK40062718A (en) | Hydrophobic interaction protein chromatography under no-salt conditions | |
| EP2938357A1 (en) | High temperature dead end antibody filtration |